| 1. |
- Carninci, P, et al.
(författare)
-
The transcriptional landscape of the mammalian genome
- 2005
-
Ingår i: Science (New York, N.Y.). - : American Association for the Advancement of Science (AAAS). - 1095-9203 .- 0036-8075. ; 309:5740, s. 1559-1563
-
Tidskriftsartikel (refereegranskat)abstract
- This study describes comprehensive polling of transcription start and termination sites and analysis of previously unidentified full-length complementary DNAs derived from the mouse genome. We identify the 5′ and 3′ boundaries of 181,047 transcripts with extensive variation in transcripts arising from alternative promoter usage, splicing, and polyadenylation. There are 16,247 new mouse protein-coding transcripts, including 5154 encoding previously unidentified proteins. Genomic mapping of the transcriptome reveals transcriptional forests, with overlapping transcription on both strands, separated by deserts in which few transcripts are observed. The data provide a comprehensive platform for the comparative analysis of mammalian transcriptional regulation in differentiation and development.
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
|
|
| 5. |
|
|
| 6. |
- Petersson, L., et al.
(författare)
-
Towards safer roads by integration of road scene monitoring and vehicle control
- 2006
-
Ingår i: The international journal of robotics research. - : SAGE Publications. - 0278-3649 .- 1741-3176. ; 25:1, s. 53-72
-
Tidskriftsartikel (refereegranskat)abstract
- In this paper we introduce the Smart Cars Project at the Australian National University/National ICT Australia, together with a discussion and an example of a driver assistance system. We present a framework for interactive driver assistance systems that includes techniques for fast-speed sign detection and classification, obstacle detection and tracking applied to pedestrian detection, and lane departure warning. In addition, the driver's actions are monitored. The integrated system uses information extracted from the road scene (speed signs, position within the lane, relative position to other cars, etc.) together with information about the driver's state, such as eye gaze and head pose, to issue adequate warnings. A touch screen monitor is used to present relevant information and allow the driver to interact with the system. The research is focused around robust algorithms that are able to run on-line. Results of on-line speed sign detection and pedestrian detection are presented in the context of a driver assistance system.
|
|
| 7. |
|
|
| 8. |
- Fletcher, L., et al.
(författare)
-
Correlating driver gaze with the road scene for driver assistance systems
- 2005
-
Ingår i: Robotics and Autonomous Systems. - : Elsevier BV. - 0921-8890 .- 1872-793X. ; 52:1, s. 71-84
-
Tidskriftsartikel (refereegranskat)abstract
- A driver assistance system (DAS) should support the driver by monitoring road and vehicle events and presenting relevant and timely information to the driver. It is impossible to know what a driver is thinking, but we can monitor the driver's gaze direction and compare it with the position of information in the driver's viewfield to make inferences. In this way, not only do we monitor the driver's actions, we monitor the driver's observations as well. In this paper we present the automated detection and recognition of road signs, combined with the monitoring of the driver's response. We present a complete system that reads speed signs in real-time, compares the driver's gaze, and provides immediate feedback if it appears the sign has been missed by the driver.
|
|
| 9. |
|
|
| 10. |
- Zelissen, P M J, et al.
(författare)
-
Effect of three treatment schedules of recombinant methionyl human leptin on body weight in obese adults: a randomized, placebo-controlled trial.
- 2005
-
Ingår i: Diabetes, obesity & metabolism. - : Wiley. - 1462-8902 .- 1463-1326. ; 7:6, s. 755-61
-
Tidskriftsartikel (refereegranskat)abstract
- AIM: The aim of this study was to evaluate the effect on body weight and safety of subcutaneously administered recombinant leptin in obese adults and to evaluate whether the timing of recombinant leptin administration influences efficacy. METHODS: A randomized, double-blind, placebo-controlled, multicentre study was designed, comprising of a 3-week dietary lead-in followed by a 12-week leptin or placebo treatment period. A total of 284 overweight and obese (body mass index 27-37.0 kg/m(2)) predominantly white (98%) women (66%) and men (34%) with a mean (+/-s.d.) 46.8+/-10.4 years of age were randomized into three treatment groups with three matching placebo groups. Recombinant leptin was administered by subcutaneous injection [10 mg/morning, 10 mg/evening or 20 mg/day (10 mg twice daily)]. Patients were counselled at baseline to reduce dietary intake by 2,100 kJ/day (500 kcal/day), and dietary advice was reinforced every 2-4 weeks. RESULTS: No statistically significant change in body weight occurred with recombinant leptin treatment compared with placebo treatment in any treatment group. No clinically significant adverse effects were observed with the exception of an increase in injection-site reactions in patients treated with recombinant leptin (83%) vs. placebo (36%). CONCLUSIONS: Administration of recombinant leptin to an overweight and obese population, in addition to a mildly energy-restricted diet, was not efficacious in terms of weight loss at the doses and schedules studied. The hypothesis that nocturnal administration of recombinant leptin might have a specific effect on weight loss was not supported.
|
|
